{"content":"<li class=\"n-box-item date-title\" data-end=\"1380340799\" data-start=\"1380254400\" data-txt=\"Friday, December 20, 2019\">Friday, September 27, 2013</li><li class=\"n-box-item sa-box-item\" data-id=\"1304012\" data-ts=\"1380317842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1304012-after-hours-top-gainers-losers-as-of-5-15-p-m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After-hours top gainers / Losers, as of 5:15 p.m</a></h4><ul>     <li>\n<b>After-hours top gainers, as of 5:15 p.m.:</b> <a href=\"https://seekingalpha.com/symbol/TWGP\" title=\"Tower Group, Inc.\">TWGP</a> <font color=\"green\">+18.6%</font>. <a href=\"https://seekingalpha.com/symbol/AUXL\" title=\"Auxilium Pharmaceuticals, Inc.\">AUXL</a> <font color=\"green\">+3.8%</font>. <a href=\"https://seekingalpha.com/symbol/HCSG\" title=\"Healthcare Services Group, Inc.\">HCSG</a> <font color=\"green\">+3.0%</font>. <a href=\"https://seekingalpha.com/symbol/CRAY\" title=\"Cray Inc\">CRAY</a> <font color=\"green\">+2.9%</font>. <a href=\"https://seekingalpha.com/symbol/PRAA\" title=\"PRA Group, Inc.\">PRAA</a> <font color=\"green\">+2.7%</font>.</li>\n<li>\n<b>After-hours top losers:</b> <a href=\"https://seekingalpha.com/symbol/SREV\" title=\"ServiceSource International, Inc.\">SREV</a> <font color=\"red\">-7.6%</font>. <a href=\"https://seekingalpha.com/symbol/HALO\" title=\"Halozyme Therapeutics, Inc.\">HALO</a> <font color=\"red\">-6.4%</font>. <a href=\"https://seekingalpha.com/symbol/ZNGA\" title=\"Zynga\">ZNGA</a> <font color=\"red\">-4.5%</font>. <a href=\"https://seekingalpha.com/symbol/RPTP\" title=\"Raptor Pharmaceutical Corp.\">RPTP</a> <font color=\"red\">-4.2%</font>. <a href=\"https://seekingalpha.com/symbol/LIN\" title=\"Linde plc\">OTC:LIN</a> <font color=\"red\">-3.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1304012\" data-linked=\"After-hours top gainers / Losers, as of 5:15 p.m\" data-tweet=\"$TWGP $AUXL $HCSG - After-hours top gainers / Losers, as of 5:15 p.m https://seekingalpha.com/news/1304012-after-hours-top-gainers-losers-as-of-5-15-p-m?source=tweet\" data-url=\"https://seekingalpha.com/news/1304012-after-hours-top-gainers-losers-as-of-5-15-p-m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303992\" data-ts=\"1380317102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSUN\" target=\"_blank\">CSUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303992-more-gains-for-chinese-solar-stocks-as-upgrades-add-to-momentum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More gains for Chinese solar stocks as upgrades add to momentum</a></h4><ul>     <li>\n<a href=\"https://seekingalpha.com/currents/post/1302412\" target=\"_blank\">Deutsche's upgrades</a> of Yingli and Trina ended up stoking a broader rally in volatile Chinese solar names, most of whom were already having a pretty impressive week going into today.</li>     <li>China Sunergy (<a href=\"https://seekingalpha.com/symbol/CSUN\" title=\"China Sunergy Co., Ltd.\">CSUN</a> <font color=\"green\">+30.4%</font>) was a standout, even though there was no company-specific news to fuel today's massive gains. Other winners: <a href=\"https://seekingalpha.com/symbol/CSIQ\" title=\"Canadian Solar Inc.\">CSIQ</a> <font color=\"green\">+9.5%</font>. <a href=\"https://seekingalpha.com/symbol/SOL\" title=\"ReneSola Ltd.\">SOL</a> <font color=\"green\">+8.8%</font>. <a href=\"https://seekingalpha.com/symbol/JKS\" title=\"JinkoSolar Holding Co., Ltd.\">JKS</a> <font color=\"green\">+5.3%</font>. <a href=\"https://seekingalpha.com/symbol/JASO\" title=\"JA Solar Holdings, Co., Ltd.\">JASO</a> <font color=\"green\">+4.1%</font>. <a href=\"https://seekingalpha.com/symbol/DQ\" title=\"DAQO New Energy Corp.\">DQ</a> <font color=\"green\">+3.7%</font>.</li>     <li>\n<a href=\"https://seekingalpha.com/currents/post/1300602\" target=\"_blank\">Yesterday:</a> Solar stocks rally again, India and First Solar in the news</li>     <li>\n<a href=\"https://seekingalpha.com/currents/post/1299052\" target=\"_blank\">Wednesday:</a> Solar stocks add to 2013 gains after tariff proposal aired</li> </ul><div class=\"tiny-share-widget\" data-id=\"1303992\" data-linked=\"More gains for Chinese solar stocks as upgrades add to momentum\" data-tweet=\"$CSUN $CSUN $CSIQ - More gains for Chinese solar stocks as upgrades add to momentum https://seekingalpha.com/news/1303992-more-gains-for-chinese-solar-stocks-as-upgrades-add-to-momentum?source=tweet\" data-url=\"https://seekingalpha.com/news/1303992-more-gains-for-chinese-solar-stocks-as-upgrades-add-to-momentum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303952\" data-ts=\"1380315814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHN\" target=\"_blank\">ACHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303952-achillion-pharmaceuticals-gives-hcv-pipeline-update-shares-collapse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achillion Pharmaceuticals gives HCV pipeline update, shares collapse</a></h4><ul>     <li>Achillion Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ACHN\" title=\"Achillion Pharmaceuticals, Inc.\">ACHN</a>) gives an HCV pipeline update.</li>     <li>Sovaprevir is still on clinical hold even though the company says it has \"addressed all issues noted in the FDA's June 29, 2013 letter.\" (<a href=\"https://seekingalpha.com/currents/post/1115832\" target=\"_blank\">previous</a>)</li>     <li>As for the sovaprevir/ACH-3102/ribavirin combo, rapid virologic response was 79%. That doesn't appear to stack up too well with results from <a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a>, <a href=\"https://seekingalpha.com/symbol/GILD\" title=\"Gilead Sciences, Inc.\">GILD</a>, and <a href=\"https://seekingalpha.com/symbol/ABBV\" title=\"AbbVie Inc.\">ABBV</a> if one assumes RVR is a good indicator of SVR. (more on this <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21145856\" target=\"_blank\">here</a>)</li>     <li>Additionally, the company indicates it will advance ACH-2684 into Phase 2 combo studies. (PR)</li>     <li>ACHN <font color=\"red\">-44%</font> AH</li> </ul><div class=\"tiny-share-widget\" data-id=\"1303952\" data-linked=\"Achillion Pharmaceuticals gives HCV pipeline update, shares collapse\" data-tweet=\"$ACHN $ACHN $BMY - Achillion Pharmaceuticals gives HCV pipeline update, shares collapse https://seekingalpha.com/news/1303952-achillion-pharmaceuticals-gives-hcv-pipeline-update-shares-collapse?source=tweet\" data-url=\"https://seekingalpha.com/news/1303952-achillion-pharmaceuticals-gives-hcv-pipeline-update-shares-collapse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303822\" data-ts=\"1380313683\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HK\" target=\"_blank\">HK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303822-halcon-resources-announces-filing-of-shelf-registration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halcon Resources announces filing of shelf registration</a></h4><ul>     <li>Halcon Resources (NYSE:<a href=\"https://seekingalpha.com/symbol/HK\" title=\"Halcon Resources Corporation\">HK</a>) <font color=\"red\">-1.8%</font> AH after filing for a ~158M-share common stock <a href=\"http://www.sec.gov/Archives/edgar/data/1282648/000104746913009372/a2216835zs-3asr.htm\" target=\"_blank\">offering</a> by selling shareholders.</li>     <li>HK is not selling any shares and will not receive any of the proceeds from the sale.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1303822\" data-linked=\"Halcon Resources announces filing of shelf registration\" data-tweet=\"$HK $HKRS - Halcon Resources announces filing of shelf registration https://seekingalpha.com/news/1303822-halcon-resources-announces-filing-of-shelf-registration?source=tweet\" data-url=\"https://seekingalpha.com/news/1303822-halcon-resources-announces-filing-of-shelf-registration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303802\" data-ts=\"1380313180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303802-the-weeks-etf-movers-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The week&#39;s ETF movers - Gainers / Losers</a></h4><ul>     <li> <b>The week's ETF movers - Gainers:</b> <a href='https://seekingalpha.com/symbol/tan' title='Guggenheim Solar ETF '>TAN</a> <font color='green'>+8.03%</font>. <a href='https://seekingalpha.com/symbol/vxx' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='green'>+2.60%</font>. <a href='https://seekingalpha.com/symbol/tlt' title='iShares 20+ Year Treasury Bond ETF'>TLT</a> <font color='green'>+1.56%</font>. <a href='https://seekingalpha.com/symbol/dba' title='PowerShares DB Agriculture ETF'>DBA</a> <font color='green'>+1.27%</font>. <a href='https://seekingalpha.com/symbol/fxy' title='CurrencyShares Japanese Yen Trust ETF'>FXY</a> <font color='green'>+1.09%</font>.  </li><li> <b>ETF Losers:</b> <a href='https://seekingalpha.com/symbol/ung' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='red'>-4.59%</font>. <a href='https://seekingalpha.com/symbol/epi' title='WisdomTree India Earnings ETF'>EPI</a> <font color='red'>-4.00%</font>. <a href='https://seekingalpha.com/symbol/gaz' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a> <font color='red'>-3.34%</font>. <a href='https://seekingalpha.com/symbol/dem' title='WisdomTree Emerging Markets Equity Income ETF'>DEM</a> <font color='red'>-3.32%</font>. <a href='https://seekingalpha.com/symbol/kol' title='Market Vectors Coal ETF'>KOL</a> <font color='red'>-3.13%</font>. </li> </ul><div class=\"tiny-share-widget\" data-id=\"1303802\" data-linked=\"The week&#39;s ETF movers - Gainers / Losers\" data-tweet=\"$TAN $VXX $TLT - The week&#39;s ETF movers - Gainers / Losers https://seekingalpha.com/news/1303802-the-weeks-etf-movers-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1303802-the-weeks-etf-movers-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303702\" data-ts=\"1380311374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARLP\" target=\"_blank\">ARLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303702-alliance-resources-pontiki-mine-in-kentucky-set-to-close\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alliance Resource&#39;s Pontiki mine in Kentucky set to close</a></h4><ul>     <li>Alliance Resource Partners (<a href=\"https://seekingalpha.com/symbol/ARLP\" title=\"Alliance Resource Partners, L.P.\">ARLP</a> <font color=\"red\">-2.4%</font>) says its Pontiki mine in Kentucky is expected to close by year end, and its Excel Mining subsidiary issued Worker Adjustment and Retraining  Notification notices to all employees at the complex.</li>     <li>ARLP does not expect the mine closure to have a material impact on 2013 financial results.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1303702\" data-linked=\"Alliance Resource&#39;s Pontiki mine in Kentucky set to close\" data-tweet=\"$ARLP - Alliance Resource&#39;s Pontiki mine in Kentucky set to close https://seekingalpha.com/news/1303702-alliance-resources-pontiki-mine-in-kentucky-set-to-close?source=tweet\" data-url=\"https://seekingalpha.com/news/1303702-alliance-resources-pontiki-mine-in-kentucky-set-to-close\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303662\" data-ts=\"1380309886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMTI\" target=\"_blank\">RMTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303662-stifel-ups-price-target-on-rockwell-medical\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel ups price target on Rockwell Medical</a></h4><ul>     <li>Rockwell Medical (<a href=\"https://seekingalpha.com/symbol/RMTI\" title=\"Rockwell Medical, Inc.\">RMTI</a> <font color=\"green\">+13.6%</font>) \u2014 which was already up some <font color=\"green\">65%</font> in September going into today on the back of this month's upbeat <a href=\"https://seekingalpha.com/currents/search?query=CRUISE-2\" target=\"_blank\">SFP </a><a href=\"https://seekingalpha.com/currents/search?query=CRUISE-2\" target=\"_blank\">CRUISE-2 results</a> \u2014 posts double-digit gains.<br>     </li>     <li>Likely behind today's strength is Stifel, where analysts have <a href=\"http://www.streetinsider.com/Analyst+PT+Change/Rockwell+Medical+%28RMTI%29+Target+Raised+to+%2418+at+Stifel/8727958.html?si_client=st\" target=\"_blank\">raised their price target</a> on the shares to $18 from $11. </li> </ul><div class=\"tiny-share-widget\" data-id=\"1303662\" data-linked=\"Stifel ups price target on Rockwell Medical\" data-tweet=\"$RMTI - Stifel ups price target on Rockwell Medical https://seekingalpha.com/news/1303662-stifel-ups-price-target-on-rockwell-medical?source=tweet\" data-url=\"https://seekingalpha.com/news/1303662-stifel-ups-price-target-on-rockwell-medical\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303612\" data-ts=\"1380308116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303612-nektar-still-attractive-after-nktrminus-181-miss-brean-william-blair\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar still attractive after NKTR-181 miss: Brean, William Blair</a></h4><ul>\n<li>William Blair and Brean are out positive on Nektar Therapeutics (<a href=\"https://seekingalpha.com/symbol/NKTR\" title=\"Nektar Therapeutics\">NKTR</a> <font color=\"red\">-19.9%</font>) amid a rather dramatic sell-off triggered by NKTR-181's Phase 2 miss. (<a href=\"https://seekingalpha.com/currents/search?query=NKTR-181\" target=\"_blank\">previous coverage</a>) </li>\n<li>Due to \"significant progress with both its proprietary and partnered programs  [and] the  breadth of development with its technology platform,\" NKTR  <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/09/3948338/william-blair-reiterates-outperform-nektar-therapeutics-\" target=\"_blank\">remains a viable asset</a>,\" William Blair's John Sonnier says.</li>\n<li>\"Perhaps more severe patients need to be enrolled in order to see a difference between drug and placebo,\" Brean's Jonathan Aschoff muses, <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/09/3948321/update-brean-capital-lowers-pt-on-nektar-therapeutics-fo\" target=\"_blank\">reiterating</a> a Buy rating but lowering his price target to $14 from $17.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1303612\" data-linked=\"Nektar still attractive after NKTR-181 miss: Brean, William Blair\" data-tweet=\"$NKTR - Nektar still attractive after NKTR-181 miss: Brean, William Blair https://seekingalpha.com/news/1303612-nektar-still-attractive-after-nktrminus-181-miss-brean-william-blair?source=tweet\" data-url=\"https://seekingalpha.com/news/1303612-nektar-still-attractive-after-nktrminus-181-miss-brean-william-blair\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303532\" data-ts=\"1380306311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWGP\" target=\"_blank\">TWGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303532-insurance-insider-tower-hires-3-banks-seeking-solutions-to-reserving-crisis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insurance Insider: Tower hires 3 banks, seeking solutions to &quot;reserving crisis&quot;</a></h4><ul>     <li>Tower Group (<a href=\"https://seekingalpha.com/symbol/TWGP\" title=\"Tower Group, Inc.\">TWGP</a> <font color=\"red\">-15.5%</font>) continue to plunge after <a href=\"http://www.insuranceinsider.com/tower-group-shares-plunge-16-percent\" target=\"_blank\">Insurance Insider reported</a>, citing sources, that the company had hired Barclays Capital, Bank of America, and JPMorgan to seek solutions to its \"reserving crisis.\"</li>     <li>Shares have <font color=\"red\">fallen 50.4%</font> since Sept. 17, when <a href=\"https://seekingalpha.com/currents/post/1285942\" target=\"_blank\">speculation arose</a> that the company could take a reserve charger higher than the previously expected $60M-$110M .</li> </ul>   <div class=\"tiny-share-widget\" data-id=\"1303532\" data-linked=\"Insurance Insider: Tower hires 3 banks, seeking solutions to &quot;reserving crisis&quot;\" data-tweet=\"$TWGP - Insurance Insider: Tower hires 3 banks, seeking solutions to &quot;reserving crisis&quot; https://seekingalpha.com/news/1303532-insurance-insider-tower-hires-3-banks-seeking-solutions-to-reserving-crisis?source=tweet\" data-url=\"https://seekingalpha.com/news/1303532-insurance-insider-tower-hires-3-banks-seeking-solutions-to-reserving-crisis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303512\" data-ts=\"1380306030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTNP\" target=\"_blank\">TTNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303512-titan-pharmaceuticals-jumps-fda-probuphine-meeting-scheduled-for-november\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titan Pharmaceuticals jumps, FDA Probuphine meeting scheduled for November</a></h4><ul>\n<li>Titan Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/TTNP\" title=\"Titan Pharmaceuticals, Inc.\">TTNP</a> <font color=\"green\">+16.4%</font>) rallies on huge volume.</li>\n<li>The FDA has granted the company a Type C meeting for November 19 to discuss exactly what went wrong with the Probuphine NDA.</li>\n<li>The company hopes the meeting will provide some \"clarity regarding the regulatory path forward\" for the buprenorphine implant. (PR)</li>\n<li>The stock <a href=\"https://seekingalpha.com/currents/post/986991\" target=\"_blank\">collapsed</a> in May when the company received the CRL.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1303512\" data-linked=\"Titan Pharmaceuticals jumps, FDA Probuphine meeting scheduled for November\" data-tweet=\"$TTNP - Titan Pharmaceuticals jumps, FDA Probuphine meeting scheduled for November https://seekingalpha.com/news/1303512-titan-pharmaceuticals-jumps-fda-probuphine-meeting-scheduled-for-november?source=tweet\" data-url=\"https://seekingalpha.com/news/1303512-titan-pharmaceuticals-jumps-fda-probuphine-meeting-scheduled-for-november\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303452\" data-ts=\"1380304667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXCM\" target=\"_blank\">DXCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303452-medtronics-minimed-approval-sinks-dexcom-hits-insulet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medtronic&#39;s MiniMed approval sinks DexCom, hits Insulet</a></h4><ul>\n<li>DexCom (<a href=\"https://seekingalpha.com/symbol/DXCM\" title=\"DexCom, Inc.\">DXCM</a> <font color=\"red\">-8.2%</font>) sinks after the <a href=\"http://www.bloomberg.com/news/2013-09-27/medtronic-wins-u-s-approval-for-artificial-pancreas-system.html\" target=\"_blank\">FDA approves</a> Medtronic's (<a href=\"https://seekingalpha.com/symbol/MDT\" title=\"Medtronic plc\">MDT</a> <font color=\"green\">+0.2%</font>) MiniMed 530G.</li>\n<li>Billed as an \"artificial pancreas,\" the device shuts down insulin delivery when it senses blood sugar levels have fallen too low.</li>\n<li>Both DXCM and Insulet (<a href=\"https://seekingalpha.com/symbol/PODD\" title=\"Insulet Corporation\">PODD</a> <font color=\"red\">-2.6%</font>) could have done without the news \u2014 the companies market glucose monitors and insulin pumps.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1303452\" data-linked=\"Medtronic&#39;s MiniMed approval sinks DexCom, hits Insulet\" data-tweet=\"$DXCM $DXCM $MDT - Medtronic&#39;s MiniMed approval sinks DexCom, hits Insulet https://seekingalpha.com/news/1303452-medtronics-minimed-approval-sinks-dexcom-hits-insulet?source=tweet\" data-url=\"https://seekingalpha.com/news/1303452-medtronics-minimed-approval-sinks-dexcom-hits-insulet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303422\" data-ts=\"1380303474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVB\" target=\"_blank\">NAVB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303422-navidea-biopharmaceuticals-jumps-after-ceo-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navidea Biopharmaceuticals jumps after CEO presentation</a></h4><ul>\n<li>Navidea Biopharmaceuticals (<a href=\"https://seekingalpha.com/symbol/NAVB\" title=\"Navidea Biopharmaceuticals\">NAVB</a> <font color=\"green\">+4.2%</font>) moves up after CEO Mark Pykett's presentation at the Biotech Industry       Conference.</li>\n<li>Pykett updated the RIGscan and Manocept programs as well as NAV4694 and NAV5001. (<a href=\"http://www.visualwebcaster.com/VWP/Player/advplayer.html?id=95779&amp;uid=6980778&amp;g=%7BF7E6B14C-3605-46F6-928F-15EB99D03D24%7D&amp;time=GEFHENGLFLGNFM&amp;digest=V5Z/ssd9ERE3sMIgRs/9nQ&amp;ls=\" target=\"_blank\">full presentation</a>)</li>\n<li>Also notable: Terren Peizer reported a 9.9% passive stake Thursday. (<a href=\"http://www.sec.gov/Archives/edgar/data/810509/000114420413052536/v355922_sc13g.htm\" target=\"_blank\">13G</a>)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1303422\" data-linked=\"Navidea Biopharmaceuticals jumps after CEO presentation\" data-tweet=\"$NAVB - Navidea Biopharmaceuticals jumps after CEO presentation https://seekingalpha.com/news/1303422-navidea-biopharmaceuticals-jumps-after-ceo-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/1303422-navidea-biopharmaceuticals-jumps-after-ceo-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303402\" data-ts=\"1380303058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CERN\" target=\"_blank\">CERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303402-cerner-climbs-on-strategic-partnership-with-intermountain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cerner climbs on strategic partnership with Intermountain</a></h4><ul>\n<li>Cerner (<a href=\"https://seekingalpha.com/symbol/CERN\" title=\"Cerner Corporation\">CERN</a> <font color=\"green\">+9.6%</font>) shares spike after the company<a href=\"http://www.cerner.com/Intermountain_and_Cerner_announce_strategic_partnership/\" target=\"_blank\"> inks</a> a multi-year strategic partnership with Intermountain (which operates 22 hospitals in Utah and Idaho) to implement Cerner's electronic medical record and revenue cycle solutions across all of Intermountain's hospitals and clinics.</li>\n<li>The collaboration also aims to leverage Intermountain's clinical processes and data as well as build a new set of tools, such as activity-based costing, for \"a post-fee-for-service world.\"</li>\n</ul>\n<ul><li>B. Riley's Gene Mannheimer <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/09/3948680/b-riley-co-s-mannheimer-says-cerner-deal-with-intermount\" target=\"_blank\">told Benzinga</a> that the partnership is \"huge\" and could be valued at \"a couple hundred million dollars.\" Making things sweeter, Cerner beat out Epic for the contract, which has recently been viewed as the<em> </em>likely winner of \"any contract up for grabs.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"1303402\" data-linked=\"Cerner climbs on strategic partnership with Intermountain\" data-tweet=\"$CERN - Cerner climbs on strategic partnership with Intermountain https://seekingalpha.com/news/1303402-cerner-climbs-on-strategic-partnership-with-intermountain?source=tweet\" data-url=\"https://seekingalpha.com/news/1303402-cerner-climbs-on-strategic-partnership-with-intermountain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303392\" data-ts=\"1380302970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNXL\" target=\"_blank\">UNXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303392-unipixel-slides-following-critical-sa-column\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UniPixel slides following critical SA column</a></h4><ul>\n<li>SA contributor <a href=\"https://seekingalpha.com/article/1717132-uni-pixel-investors-getting-fooled-again\" target=\"_blank\">Alpha Exposure</a>, who has been bearish on UniPixel (<a href=\"https://seekingalpha.com/symbol/UNXL\" title=\"Uni-Pixel, Inc.\">UNXL</a> <font color=\"red\">-3.8%</font>) for a while (<a href=\"https://seekingalpha.com/currents/post/1099382\" target=\"_blank\">previous</a>), calls the business update PR that led shares to <a href=\"https://seekingalpha.com/currents/post/1298452\" target=\"_blank\">blast off </a>on Wednesday \"misleading.\"</li>\n<li>The author thinks the PR makes it clear UniPixel will miss its Oct. 1 deadline for shipping its InTouch sensors, and believes the fact UniPixel only said InTouch will see a commercial rollout in the \"weeks and months ahead\" indicates the company is \"nowhere close\" to launching InTouch.</li>\n<li>Alpha Exposure also thinks InTouch isn't yet \"qualified or certified for production,\" given UniPixel hasn't issued a PR announcing the news, and argues rivals such as China's <a href=\"http://www.digitimes.com/news/a20130924PD210.html\" target=\"_blank\">O-Film Tech</a> are making headway in the interim.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1303392\" data-linked=\"UniPixel slides following critical SA column\" data-tweet=\"$UNXL - UniPixel slides following critical SA column https://seekingalpha.com/news/1303392-unipixel-slides-following-critical-sa-column?source=tweet\" data-url=\"https://seekingalpha.com/news/1303392-unipixel-slides-following-critical-sa-column\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303382\" data-ts=\"1380302087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARQL\" target=\"_blank\">ARQL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303382-arqule-rallies-on-renewed-hopes-for-tivantinib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArQule rallies on renewed hopes for tivantinib</a></h4><ul>\n<li>Today's rally in shares of ArQule (<a href=\"https://seekingalpha.com/symbol/ARQL\" title=\"ArQule, Inc.\">ARQL</a> <font color=\"green\">+9.7%</font>) is likely attributable to RBC's Adnan Butt, who Reuters quotes as saying that an upcoming presentation at ESMO <a href=\"http://www.reuters.com/article/2013/09/27/arqule-idUSL4N0HN38F20130927\" target=\"_blank\">could mean another shot</a> for tivantinib in lung cancer.</li>\n<li> The drug was effectively left for dead (at least as far as NSCLC goes) last October when ARQL and partner Daiichi Sankyo (<a href=\"https://seekingalpha.com/symbol/DSKYF\" title=\"Daiichi Sankyo Co., Ltd.\">OTCPK:DSKYF</a>) dropped a Phase 3 trial due to lack of efficacy.<br>\n</li>\n<li>New data from that trial \"could validate the mechanism of action for the drug and potentially allow a path forward in lung cancer as well,\" Butt says.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1303382\" data-linked=\"ArQule rallies on renewed hopes for tivantinib\" data-tweet=\"$ARQL $ARQL $DSKYF - ArQule rallies on renewed hopes for tivantinib https://seekingalpha.com/news/1303382-arqule-rallies-on-renewed-hopes-for-tivantinib?source=tweet\" data-url=\"https://seekingalpha.com/news/1303382-arqule-rallies-on-renewed-hopes-for-tivantinib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303372\" data-ts=\"1380301670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACN\" target=\"_blank\">ACN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303372-accenture-slides-following-fq4-report-takes-ibm-lower-with-it\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Accenture slides following FQ4 report, takes IBM lower with it</a></h4><ul>\n<li>The soft revenue and bookings <a href=\"https://seekingalpha.com/currents/post/1301552\" target=\"_blank\">guidance</a> provided with Accenture's (<a href=\"https://seekingalpha.com/symbol/ACN\" title=\"Accenture plc\">ACN</a> <font color=\"red\">-3.8%</font>) <a href=\"https://seekingalpha.com/currents/post/1301442\" target=\"_blank\">FQ4 results</a> are oveshadowing the company's <a href=\"https://seekingalpha.com/currents/post/1301632\" target=\"_blank\">dividend hike</a> and $5B buyback expansion. Consulting/outsourcing rival IBM (<a href=\"https://seekingalpha.com/symbol/IBM\" title=\"International Business Machines Corporation\">IBM</a> <font color=\"red\">-1.7%</font>) is trading lower in sympathy. Wipro (<a href=\"https://seekingalpha.com/symbol/WIT\" title=\"Wipro Limited\">WIT</a> <font color=\"red\">-3.2%</font>) is also selling off, but outsourcing peers Infosys (<a href=\"https://seekingalpha.com/symbol/INFY\" title=\"Infosys Limited, Inc.\">INFY</a> <font color=\"red\">-0.3%</font>) and Cognizant (<a href=\"https://seekingalpha.com/symbol/CTSH\" title=\"Cognizant Technology Solutions Corporation\">CTSH</a> <font color=\"red\">-0.6%</font>) have pared their morning losses.</li>\n<li>Accenture's CC remarks (<a href=\"https://seekingalpha.com/article/1716402-accenture-management-discusses-q4-2013-results-earnings-call-transcript\" target=\"_blank\">transcript</a>) likely aren't helping. CFO David Rowland mentioned that while outsourcing bookings were healthy (book-to-bill of 1.4), all 3 consulting bookings segments - management consulting, tech consulting, and systems integration - were at the low end of its B2B guidance ranges. Total consulting B2B was 1.0</li>\n<li>Rowland adds Accenture thinks the \"cycle of lower growth\" it has seen in recent quarters \"won't change much\" near-term.</li>\n<li>Echoing comments from Cisco's <a href=\"https://seekingalpha.com/currents/post/1303202\" target=\"_blank\">John Chambers</a>, CEO Pierre Nanterme mentioned Accenture is seeing more emerging markets \"volatility,\" even as the U.S. performs well and Europe stabilizes.</li>\n<li>Janney's Joseph Foresi is <a href=\"http://finance.yahoo.com/news/accenture-falls-disappointing-guidance-144152158.html\" target=\"_blank\">staying bullish</a>, arguing Accenture is \"well positioned given its high end capabilities to gain market share as outsourcing becomes more commoditized.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1303372\" data-linked=\"Accenture slides following FQ4 report, takes IBM lower with it\" data-tweet=\"$ACN $ACN $IBM - Accenture slides following FQ4 report, takes IBM lower with it https://seekingalpha.com/news/1303372-accenture-slides-following-fq4-report-takes-ibm-lower-with-it?source=tweet\" data-url=\"https://seekingalpha.com/news/1303372-accenture-slides-following-fq4-report-takes-ibm-lower-with-it\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303332\" data-ts=\"1380301134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GERN\" target=\"_blank\">GERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303332-geron-marches-higher-ahead-of-imetelstat-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Geron marches higher ahead of imetelstat data</a></h4><ul>     <li>This month's big Geron (<a href=\"https://seekingalpha.com/symbol/GERN\" title=\"Geron Corporation\">GERN</a> <font color=\"green\">+11.9%</font>) rally takes another leg higher. With today's move, the shares are up around <strong><font color=\"green\">151%</font> </strong>in September.</li>     <li>At least one trader in the options market thinks the rally has further to go: The purchase of 3K November 3 strike calls was <a href=\"http://finance.yahoo.com/news/bullish-call-spread-targets-geron-153603419.html\" target=\"_blank\">partially funded</a> by the sale of 3K November 5 strike calls. Although the upside in this trade is capped, there's still a nice profit to be made if GERN trades up to or above $5 by expiration.</li>     <li>A bet for GERN <a href=\"http://www.thestreet.com/story/12050599/4/biotech-stock-mailbag-celldex-exelixis-geron-nps-pharma.html\" target=\"_blank\">is a bet on</a> imetelstat in myelofibrosis \u2014 look for interim data at ASH in December.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1303332\" data-linked=\"Geron marches higher ahead of imetelstat data\" data-tweet=\"$GERN - Geron marches higher ahead of imetelstat data https://seekingalpha.com/news/1303332-geron-marches-higher-ahead-of-imetelstat-data?source=tweet\" data-url=\"https://seekingalpha.com/news/1303332-geron-marches-higher-ahead-of-imetelstat-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303292\" data-ts=\"1380300351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303292-midday-top-10-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday top 10 Gainers / Losers</a></h4><ul>     <li>\n<b>Midday top 10 gainers:</b> <a href=\"https://seekingalpha.com/symbol/AMCF\" title=\"Andatee China Marine Fuel Services Corporation\">OTC:AMCF</a> <font color=\"green\">+141%</font>. <a href=\"https://seekingalpha.com/symbol/PME\" title=\"Pingtan Marine Enterprise Ltd.\">PME</a> <font color=\"green\">+37%</font>. <a href=\"https://seekingalpha.com/symbol/AEHR\" title=\"Aehr Test Systems\">AEHR</a> <font color=\"green\">+36%</font>. <a href=\"https://seekingalpha.com/symbol/IIN\" title=\"IntriCon Corporation\">IIN</a> <font color=\"green\">+29%</font>. <a href=\"https://seekingalpha.com/symbol/CSUN\" title=\"China Sunergy Co., Ltd.\">CSUN</a> <font color=\"green\">+23%</font>. SPPR <font color=\"green\">+18%</font>. <a href=\"https://seekingalpha.com/symbol/TSL\" title=\"Trina Solar Limited\">TSL</a> <font color=\"green\">+16%</font>. <a href=\"https://seekingalpha.com/symbol/ZIOP\" title=\"ZIOPHARM Oncology, Inc.\">ZIOP</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/ARQL\" title=\"ArQule, Inc.\">ARQL</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/CNTF\" title=\"China TechFaith Wireless Communication Technology Limited\">CNTF</a> <font color=\"green\">+13%</font>.</li>\n<li>\n<b>Midday top 10 Losers:</b> <a href=\"https://seekingalpha.com/symbol/NKTR\" title=\"Nektar Therapeutics\">NKTR</a> <font color=\"red\">-23%</font>. <a href=\"https://seekingalpha.com/symbol/TWGP\" title=\"Tower Group, Inc.\">TWGP</a> <font color=\"red\">-14%</font>. <a href=\"https://seekingalpha.com/symbol/CHRM\" title=\"Charm Communications Inc.\">CHRM</a> <font color=\"red\">-14%</font>. <a href=\"https://seekingalpha.com/symbol/ICEL\" title=\"Cellular Dynamics International, Inc.\">ICEL</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/ZOLT\" title=\"Zoltek Companies, Inc.\">ZOLT</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/LL\" title=\"Lumber Liquidators Holdings, Inc.\">LL</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/JCP\" title=\"J.C. Penney Company Inc.\">JCP</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/KIOR\" title=\"KiOR, Inc.\">KIOR</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/FU\" title=\"FAB Universal Corp.\">FU</a> <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1303292\" data-linked=\"Midday top 10 Gainers / Losers\" data-tweet=\"$AMCF $PME $AEHR - Midday top 10 Gainers / Losers https://seekingalpha.com/news/1303292-midday-top-10-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1303292-midday-top-10-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303272\" data-ts=\"1380300163\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303272-ziopharm-oncology-shares-rally-company-presents-at-conference\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm Oncology shares rally, company presents at conference</a></h4><ul>\n<li>Shares of Ziopharm Oncology (<a href=\"https://seekingalpha.com/symbol/ZIOP\" title=\"ZIOPHARM Oncology, Inc.\">ZIOP</a> <font color=\"green\">+18.2%</font>) post double-digit gains.</li>\n<li>The company presented today at the Biotech Industry Conference in New York.<br>\n</li>\n<li>In the presentation, ZIOP says it is \"the farthest advanced at regulating gene function in vivo in humans\" and notes that it expects to have \"at least 8 INDs through 2015.\"</li>\n<li>The company also says data is set to be presented \"near-term\" at multiple conferences. (<a href=\"http://www.sec.gov/Archives/edgar/data/1107421/000119312513381072/d606430dex991.htm\" target=\"_blank\">full presentation</a>)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1303272\" data-linked=\"Ziopharm Oncology shares rally, company presents at conference\" data-tweet=\"$ZIOP - Ziopharm Oncology shares rally, company presents at conference https://seekingalpha.com/news/1303272-ziopharm-oncology-shares-rally-company-presents-at-conference?source=tweet\" data-url=\"https://seekingalpha.com/news/1303272-ziopharm-oncology-shares-rally-company-presents-at-conference\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303242\" data-ts=\"1380299485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDX\" target=\"_blank\">CLDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303242-celldex-extends-rally-as-investors-anticipate-study-read-outs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celldex extends rally as investors anticipate study read-outs</a></h4><ul>     <li>Shares of Celldex (<a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color='green'>+5.3%</font>) continue to rally and with today's gains are up about <font color='green'>30%</font> this week and around <font color='green'>70%</font> this month.</li>     <li>Behind this week's move are a series of <a href=\"https://seekingalpha.com/currents/post/1295912\" target=\"_blank\">analyst upgrades</a> and a positive <a href=\"https://seekingalpha.com/currents/post/1300672\" target=\"_blank\">Jim Cramer mention</a>.</li>     <li>Today, <em>TheStreet</em>'s Adam Feuerstein said he \"doesn't dislike CLDX\" and notes that \"there are compelling reasons to own [the stock even as] the valuation is getting ahead of itself.\"</li>     <li>This is about as close to a bullish call as you're likely to get with  Feuerstein, and the often skeptical columnist also notes that CLDX has pipeline assets hitting two popular drug development trends: CDX-1135 checks the \"rare, or orphan, diseases\" box and <a href=\"https://seekingalpha.com/currents/search?query=CDX-1127\" target=\"_blank\">CDX-1127</a> plays to investors' affinity for cancer immunotherapies. (<a href=\"http://www.thestreet.com/story/12050599/1/biotech-stock-mailbag-celldex-exelixis-geron-nps-pharma.html\" target=\"_blank\">full article</a>)</li> </ul><div class=\"tiny-share-widget\" data-id=\"1303242\" data-linked=\"Celldex extends rally as investors anticipate study read-outs\" data-tweet=\"$CLDX - Celldex extends rally as investors anticipate study read-outs https://seekingalpha.com/news/1303242-celldex-extends-rally-as-investors-anticipate-study-read-outs?source=tweet\" data-url=\"https://seekingalpha.com/news/1303242-celldex-extends-rally-as-investors-anticipate-study-read-outs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303162\" data-ts=\"1380297501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXAS\" target=\"_blank\">AXAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303162-abraxas-petroleum-moves-higher-after-operations-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abraxas Petroleum moves higher after operations update</a></h4><ul>     <li>Abraxas Petroleum (<a href=\"https://seekingalpha.com/symbol/AXAS\" title=\"Abraxas Petroleum Corporation\">AXAS</a> <font color=\"green\">+1.9%</font>) is higher after providing an update on its operations at Williston Basin, Eagle Ford Shale and Permian Basin.</li>     <li>AXAS says drilling operations on the Lillibridge West pad at Williston Basin in North Dakota are now effectively complete a month ahead of schedule, and completion of the four-well pad is scheduled for late October.</li>     <li>At Eagle Ford Shale in Texas, AXAS is currently rigging up on the Blue Eyes 1H at its Jourdanton prospect; AXAS holds a 100% working interest in Blue Eyes 1H.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1303162\" data-linked=\"Abraxas Petroleum moves higher after operations update\" data-tweet=\"$AXAS - Abraxas Petroleum moves higher after operations update https://seekingalpha.com/news/1303162-abraxas-petroleum-moves-higher-after-operations-update?source=tweet\" data-url=\"https://seekingalpha.com/news/1303162-abraxas-petroleum-moves-higher-after-operations-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1303052\" data-ts=\"1380294729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1303052-omeros-spikes-on-orphan-drug-designation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros spikes on orphan drug designation</a></h4><ul><li>Omeros (<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+3.2%</font>) shares spike after the FDA <a href=\"http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=400213\" target=\"_blank\">grants</a>&nbsp;the company an orphan drug designation for its&nbsp;<a href=\"https://seekingalpha.com/currents/post/1056891\" target=\"_blank\">OMS824 antibody</a> for the treatment of Huntington's.</li></ul><div class=\"tiny-share-widget\" data-id=\"1303052\" data-linked=\"Omeros spikes on orphan drug designation\" data-tweet=\"$OMER - Omeros spikes on orphan drug designation https://seekingalpha.com/news/1303052-omeros-spikes-on-orphan-drug-designation?source=tweet\" data-url=\"https://seekingalpha.com/news/1303052-omeros-spikes-on-orphan-drug-designation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302942\" data-ts=\"1380292717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302942-linkedin-sees-profit-taking-after-itg-cuts-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LinkedIn sees profit-taking after ITG cuts estimates</a></h4><ul><li>Citing weak order volumes, <a href=\"https://twitter.com/thenotablecalls/status/383585247524163584\" target=\"_blank\">ITG has cut</a> its Q3 LinkedIn (LNKD <font color='red'>-2.4%</font>) estimates.</li><li>Shares are selling off after rallying to within striking distance of their 52-week high yesterday, thanks in part to a <a href=\"https://seekingalpha.com/currents/post/1301152\" target=\"_blank\">bullish Wunderlich note</a>. Both Wunderlich and <a href=\"https://seekingalpha.com/currents/post/1296852\" target=\"_blank\">Evercore</a> have stated this week their Q3 LinkedIn checks have turned up positive.</li><li><a href=\"https://seekingalpha.com/currents/post/1149172\" target=\"_blank\">In July</a>, ITG lowered its Q2 numbers for LinkedIn to a range of $360M-$365M. The company <a href=\"https://seekingalpha.com/currents/post/1187082\" target=\"_blank\">wound up posting</a> Q2 revenue of $363.7M (above a $353.9M consensus).</li></ul><div class=\"tiny-share-widget\" data-id=\"1302942\" data-linked=\"LinkedIn sees profit-taking after ITG cuts estimates\" data-tweet=\"$MSFT - LinkedIn sees profit-taking after ITG cuts estimates https://seekingalpha.com/news/1302942-linkedin-sees-profit-taking-after-itg-cuts-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/1302942-linkedin-sees-profit-taking-after-itg-cuts-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302932\" data-ts=\"1380292632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302932-ceo-departure-rumors-at-ford-now-in-the-backdrop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CEO departure rumors at Ford now in the backdrop</a></h4><ul> <li>Shares of Ford (<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a> <font color='red'>-0.8%</font>) are mildly under-performing market averages today as news that CEO Alan Mulally is on the <a href=\"https://seekingalpha.com/currents/post/1302632\" target=\"_blank\">hot list</a> to take the top job at Microsoft adds to the backdrop.</li> <li>Mulally has been at Ford since 2006 and is widely credited for navigating the automaker successfully during the period.</li> <li>Ford COO Mark Fields told the <em>Detroit News</em> earlier today that the departure rumors are <a href=\"http://www.detroitnews.com/article/20130927/AUTO0102/309270065/1148/auto01/Fields-Mulally-rumors-not-distraction-Ford\" target=\"_blank\">not a distraction</a> for the automaker.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302932\" data-linked=\"CEO departure rumors at Ford now in the backdrop\" data-tweet=\"$F - CEO departure rumors at Ford now in the backdrop https://seekingalpha.com/news/1302932-ceo-departure-rumors-at-ford-now-in-the-backdrop?source=tweet\" data-url=\"https://seekingalpha.com/news/1302932-ceo-departure-rumors-at-ford-now-in-the-backdrop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302912\" data-ts=\"1380291791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302912-clovis-trades-up-on-leerink-chatter-but-astrazeneca-drug-may-be-threat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis trades up on Leerink chatter but AstraZeneca drug may be threat</a></h4><ul>\n<li>Clovis Oncology (<a href=\"https://seekingalpha.com/symbol/CLVS\" title=\"Clovis Oncology\">CLVS</a> <font color=\"green\">+1.9%</font>) reverses opening losses to trade higher.</li>\n<li>There's <a href=\"https://twitter.com/adamfeuerstein/status/383589943924125696/photo/1\" target=\"_blank\">chatter</a> that a late breaker European Cancer Congress abstract for AstraZeneca's (<a href=\"https://seekingalpha.com/symbol/AZN\" title=\"AstraZeneca Group plc\">AZN</a> <font color=\"red\">-0.6%</font>)  EGFR inhibitor AZD9291 is bad news for CLVS' CO-1686 (see also <a href=\"https://seekingalpha.com/symbol/ARIA\" title=\"ARIAD Pharmaceuticals, Inc.\">ARIA</a>'s <a href=\"https://seekingalpha.com/currents/search?query=AP26113\" target=\"_blank\">AP26113</a>).</li>\n<li>However, an upbeat note out of Leerink seems to be driving bullish sentiment. The firm <a href=\"https://twitter.com/ColfaxCapital/status/383581498093215744\" target=\"_blank\">apparently thinks</a> CLVS is worth between $96-140/share (so a really narrow range there) even without a takeout premium.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1302912\" data-linked=\"Clovis trades up on Leerink chatter but AstraZeneca drug may be threat\" data-tweet=\"$CLVS $CLVS $AZN - Clovis trades up on Leerink chatter but AstraZeneca drug may be threat https://seekingalpha.com/news/1302912-clovis-trades-up-on-leerink-chatter-but-astrazeneca-drug-may-be-threat?source=tweet\" data-url=\"https://seekingalpha.com/news/1302912-clovis-trades-up-on-leerink-chatter-but-astrazeneca-drug-may-be-threat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302872\" data-ts=\"1380291599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNG\" target=\"_blank\">RNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302872-ringcentral-surges-following-ipo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RingCentral surges following IPO</a></h4><ul>     <li>RingCentral's (<a href=\"https://seekingalpha.com/symbol/RNG\" title=\"RingCentral, Inc.\">RNG</a>) IPO is going better than <a href=\"https://seekingalpha.com/currents/post/1302822\" target=\"_blank\">Violin Memory's</a>. After <a href=\"https://seekingalpha.com/currents/post/1301952\" target=\"_blank\">pricing </a>its 7.5M-share offering at $13 last night, the VoIP/Web conferencing services firm opened at $17.25 and is currently at $18.12, <strong><font color=\"green\">up 39.4%</font></strong>. That's good for a market cap of $1.1B.</li>     <li>Rival 8x8 (<a href=\"https://seekingalpha.com/symbol/EGHT\" title=\"8X8 Inc\">EGHT</a> <font color=\"red\">-1.8%</font>), which had rallied over the last month and closed yesterday near its 52-week high, is selling off a bit today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302872\" data-linked=\"RingCentral surges following IPO\" data-tweet=\"$RNG $RNG $EGHT - RingCentral surges following IPO https://seekingalpha.com/news/1302872-ringcentral-surges-following-ipo?source=tweet\" data-url=\"https://seekingalpha.com/news/1302872-ringcentral-surges-following-ipo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302842\" data-ts=\"1380291264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZZ\" target=\"_blank\">AZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302842-azz-opens-minus-9_4-percent-after-issuing-downside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AZZ opens -9.4% after issuing downside guidance</a></h4><ul>     <li>AZZ (<a href=\"https://seekingalpha.com/symbol/AZZ\" title=\"AZZ incorporated\">AZZ</a> <font color=\"red\">-9.4%</font>) opens sharply lower after <a href=\"https://seekingalpha.com/currents/post/1302092\" target=\"_blank\">FQ2 earnings</a> rose 3.1% but the electrical equipment and components manufacturer lowered its outlook for the year and projected weak results for the current quarter.</li>\n<li>For Q3, AZZ sees EPS of $0.65-$0.75 vs. $0.95 consensus estimate and revenues of $210M-$230M vs. $251M consensus; for FY 2014, sees EPS of $2.45-$2.65 vs. $2.83 consensus and revenues of $780M-$810M vs. $844M consensus.</li>     <li>The company warned that delays in new construction for domestic and international nuclear power projects and the delayed start for the Gulf coast \"petrochemical renaissance\u201d have resulted in a significant portion of its backlog in the electrical and industrial segment to move out of the fiscal year's H2.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302842\" data-linked=\"AZZ opens -9.4% after issuing downside guidance\" data-tweet=\"$AZZ - AZZ opens -9.4% after issuing downside guidance https://seekingalpha.com/news/1302842-azz-opens-minus-9_4-percent-after-issuing-downside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/1302842-azz-opens-minus-9_4-percent-after-issuing-downside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302822\" data-ts=\"1380290438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMEM\" target=\"_blank\">VMEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302822-violin-memory-ipo-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Violin Memory IPO disappoints</a></h4><ul>     <li>After <a href=\"https://seekingalpha.com/currents/post/1301942\" target=\"_blank\">pricing</a> its 18M-share IPO at $9 last night, Violin Memory (NYSE:<a href=\"https://seekingalpha.com/symbol/VMEM\" title=\"Violin Memory, Inc.\">VMEM</a>) opened at $7.50 and is currently at $7.77, <font color=\"red\">down 13.7%</font>. That gives the enterprise flash storage system vendor a market cap of $636M. The company was valued at $800M+ in a <a href=\"http://venturebeat.com/2012/03/30/violin-memory-raises-50m-round-at-800m-plus-valuation/\" target=\"_blank\">VC funding round</a> last year.</li>     <li>GSV Capital (<a href=\"https://seekingalpha.com/symbol/GSVC\" title=\"GSV Capital\">GSVC</a> <font color=\"red\">-2.6%</font>), which estimated its Violin stake was worth $14.4M at the end of Q2 (5.8% of the firm's NAV), is selling off in sympathy. Violin rival Fusion-io (<a href=\"https://seekingalpha.com/symbol/FIO\" title=\"Fusion-io, Inc.\">FIO</a> <font color=\"red\">-1.6%</font>) is moderately lower.</li>     <li>\n<a href=\"http://www.sec.gov/Archives/edgar/data/1407190/000119312513367186/d366503ds1a.htm\" target=\"_blank\">S-1</a>, <a href=\"https://seekingalpha.com/article/1715982-ipo-preview-violin-memory\" target=\"_blank\">IPO preview</a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302822\" data-linked=\"Violin Memory IPO disappoints\" data-tweet=\"$VMEM $VMEM $SSSS - Violin Memory IPO disappoints https://seekingalpha.com/news/1302822-violin-memory-ipo-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/1302822-violin-memory-ipo-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302802\" data-ts=\"1380290284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IP\" target=\"_blank\">IP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302802-international-paper-lower-after-deutsche-bank-takes-a-dimmer-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Paper lower after Deutsche Bank takes a dimmer view</a></h4><ul> <li>Shares of International Paper (<a href=\"https://seekingalpha.com/symbol/IP\" title=\"International Paper Co.\">IP</a> <font color=\"red\">-4%</font>) dip after Deutsche Bank <a href=\"https://twitter.com/Benzinga/status/383540324234043392\" target=\"_blank\">downgrades</a> the company to a Hold rating.</li> <li>The investment firm also lowered its price target on International Paper to $51 and reduced profit estimates.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302802\" data-linked=\"International Paper lower after Deutsche Bank takes a dimmer view\" data-tweet=\"$IP - International Paper lower after Deutsche Bank takes a dimmer view https://seekingalpha.com/news/1302802-international-paper-lower-after-deutsche-bank-takes-a-dimmer-view?source=tweet\" data-url=\"https://seekingalpha.com/news/1302802-international-paper-lower-after-deutsche-bank-takes-a-dimmer-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302772\" data-ts=\"1380289811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302772-summer-street-questions-prospects-for-afrezza-nda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summer Street questions prospects for Afrezza NDA</a></h4><ul>\n<li>Summer Street takes a pot shot at Mannkind (<a href=\"https://seekingalpha.com/symbol/MNKD\" title=\"MannKind Corporation\">MNKD</a> <font color=\"red\">-0.7%</font>) Friday.</li>\n<li>Analyst Bart Classen apparently isn't convinced that the world is ready for the company's inhaled insulin product, saying there is a \"real\" chance that the FDA <a href=\"http://www.streetinsider.com/Analyst+Comments/Mannkind+%28MNKD%29+Afrezza+NDA+Might+Not+Be+Accepted+-+Summer+Street/8727009.html\" target=\"_blank\">will not accept</a> MNKD's NDA for <a href=\"https://seekingalpha.com/currents/search?query=afrezza\" target=\"_blank\">Afrezza</a>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1302772\" data-linked=\"Summer Street questions prospects for Afrezza NDA\" data-tweet=\"$MNKD - Summer Street questions prospects for Afrezza NDA https://seekingalpha.com/news/1302772-summer-street-questions-prospects-for-afrezza-nda?source=tweet\" data-url=\"https://seekingalpha.com/news/1302772-summer-street-questions-prospects-for-afrezza-nda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302752\" data-ts=\"1380289713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAM\" target=\"_blank\">AKAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302752-a-roundup-of-tech-ratings-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">A roundup of tech ratings changes</a></h4><ul><li>Akamai (<a href='https://seekingalpha.com/symbol/AKAM' title='Akamai Technologies, Inc.'>AKAM</a> <font color='red'>-2.1%</font>) has been cut to Neutral by B. Riley.</li><li>China Unicom (<a href='https://seekingalpha.com/symbol/CHU' title='China Unicom &#40;Hong Kong&#41; Limited'>CHU</a> <font color='red'>-0.7%</font>) has been cut to Hold by BNP Paribas.</li><li>Esterline Technologies (<a href='https://seekingalpha.com/symbol/ESL' title='Esterline Technologies Corporation'>ESL</a> <font color='red'>-1.8%</font>) has been cut to Underperform by BofA/Merrill.</li><li>Orbcomm (<a href='https://seekingalpha.com/symbol/ORBC' title='ORBCOMM Inc.'>ORBC</a> <font color='green'>+0.6%</font>) has been started at Buy by Chardan Capital.</li></ul><div class=\"tiny-share-widget\" data-id=\"1302752\" data-linked=\"A roundup of tech ratings changes\" data-tweet=\"$AKAM $AKAM $CHU - A roundup of tech ratings changes https://seekingalpha.com/news/1302752-a-roundup-of-tech-ratings-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/1302752-a-roundup-of-tech-ratings-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302742\" data-ts=\"1380289678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302742-airline-stocks-slump-on-downgrade-and-shutdown-fears\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airline stocks slump on downgrade and shutdown fears</a></h4><ul> <li>Airline stocks fall in early trading as the industry is increasingly viewed as more at risk from a <a href=\"http://www.nytimes.com/2013/09/28/us/politics/senate-is-expected-to-approve-budget-bill.html\" target=\"_blank\">government shutdown</a> than others.</li> <li>United Continental (<a href=\"https://seekingalpha.com/symbol/UAL\" title=\"United Continental Holdings, Inc\">UAL</a> <font color=\"red\">-7.5%</font>) is also getting hit with a <a href=\"https://twitter.com/usratings/status/383578164309397504\" target=\"_blank\">downgrade</a> from Buckingham Research to a Hold rating from Buy.</li> <li>Decliners: Delta Air Lines (NYSE:<a href=\"https://seekingalpha.com/symbol/DAL\" title=\"Delta Air Lines, Inc.\">DAL</a>) <font color=\"red\">-3.4%</font>, Spirit Airlines (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SAVE\" title=\"Spirit Airlines\">SAVE</a>) <font color=\"red\">-2.1%</font>, US Airways (<a href=\"https://seekingalpha.com/symbol/LCC\" title=\"\">LCC</a>) <font color=\"red\">-2.0%</font>, JetBlue (NASDAQ:<a href=\"https://seekingalpha.com/symbol/JBLU\" title=\"JetBlue Airways Corporation\">JBLU</a>) <font color=\"red\">-1.6%</font>, Alaska Air (NYSE:<a href=\"https://seekingalpha.com/symbol/ALK\" title=\"Alaska Air Group, Inc.\">ALK</a>) <font color=\"red\">-1.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302742\" data-linked=\"Airline stocks slump on downgrade and shutdown fears\" data-tweet=\"$UAL $UAL $DAL - Airline stocks slump on downgrade and shutdown fears https://seekingalpha.com/news/1302742-airline-stocks-slump-on-downgrade-and-shutdown-fears?source=tweet\" data-url=\"https://seekingalpha.com/news/1302742-airline-stocks-slump-on-downgrade-and-shutdown-fears\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302652\" data-ts=\"1380288237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPRS\" target=\"_blank\">EPRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302652-zalicus-gets-orphan-designation-for-postherpetic-neuralgia-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zalicus gets Orphan designation for postherpetic neuralgia drug</a></h4><ul>     <li>Zalicus (ZLCS) jumps <font color=\"green\">7.8%</font> premarket after the FDA grants an <a href=\"http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=387412\" target=\"_blank\">Orphan designation</a> for the company's postherpetic neuralgia treatment. <br>     </li>\n<li>Last week, SA contributor Medical Stock Analyst said ZLCS has \"<a href=\"https://seekingalpha.com/article/1705242-zalicus-is-a-promising-biotech-with-echoes-of-acadia-pharmaceuticals\" target=\"_blank\">echoes of Acadia</a>.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302652\" data-linked=\"Zalicus gets Orphan designation for postherpetic neuralgia drug\" data-tweet=\"$EPRS - Zalicus gets Orphan designation for postherpetic neuralgia drug https://seekingalpha.com/news/1302652-zalicus-gets-orphan-designation-for-postherpetic-neuralgia-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/1302652-zalicus-gets-orphan-designation-for-postherpetic-neuralgia-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302602\" data-ts=\"1380287739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302602-premarket-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CERE' title='Ceres, Inc.'>CERE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/RDA' title='RDA Microelectronics, Inc.'>RDA</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/FU' title='FAB Universal Corp.'>FU</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ZOLT' title='Zoltek Companies, Inc.'>ZOLT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LL' title='Lumber Liquidators Holdings, Inc.'>LL</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1302602\" data-linked=\"Premarket Gainers / Losers\" data-tweet=\"$ARQL $CERE $RDA - Premarket Gainers / Losers https://seekingalpha.com/news/1302602-premarket-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1302602-premarket-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302572\" data-ts=\"1380287322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MT\" target=\"_blank\">MT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302572-arcelormittal-kumba-iron-ore-in-talks-on-new-south-african-supply-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArcelorMittal, Kumba Iron Ore in talks on new South African supply deal</a></h4><ul>     <li>ArcelorMittal (NYSE:<a href=\"https://seekingalpha.com/symbol/MT\" title=\"ArcelorMittal\">MT</a>) and Kumba Iron Ore (<a href=\"https://seekingalpha.com/symbol/KIROY\" title=\"Kumba Iron Ore Ltd. ADR\">OTCPK:KIROY</a>) say they are in talks over a <a href=\"http://www.reuters.com/article/2013/09/27/us-arcelor-kumba-idUSBRE98Q09H20130927\" target=\"_blank\">potential new ore supply agreement</a>, as the companies try to resolve a rights and pricing dispute spanning more than three years.</li>     <li>Kumba, a unit of Anglo American (<a href=\"https://seekingalpha.com/symbol/AAUKF\" title=\"Anglo American plc\">OTCQX:AAUKF</a>, <a href=\"https://seekingalpha.com/symbol/AAUKY\" title=\"Anglo American plc ADR\">OTCPK:AAUKY</a>), had suspended an agreement with MT in 2010 under which it sold South African iron ore at a discounted price of production costs; the deal was in place because MT had a mining right in Kumba's Sishen mine that lapsed.</li>     <li>MT <font color=\"red\">-1.7%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302572\" data-linked=\"ArcelorMittal, Kumba Iron Ore in talks on new South African supply deal\" data-tweet=\"$MT $MT $KIROY - ArcelorMittal, Kumba Iron Ore in talks on new South African supply deal https://seekingalpha.com/news/1302572-arcelormittal-kumba-iron-ore-in-talks-on-new-south-african-supply-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/1302572-arcelormittal-kumba-iron-ore-in-talks-on-new-south-african-supply-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302512\" data-ts=\"1380286001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNDN\" target=\"_blank\">DNDN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302512-dendreon-to-present-provenge-data-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dendreon to present Provenge data, shares up</a></h4><ul>     <li>Dendreon (NASDAQ:<a href=\"https://seekingalpha.com/symbol/DNDN\" title=\"Dendreon Corporation\">DNDN</a>) will present Provenge data at the European Cancer Congress.</li>     <li>The company says results from two studies show a \"robust immune response when Provenge is administered with abiraterone acetate [and] suggest long-lived immunological memory       to Provenge years following initial treatment.\" (PR)</li>     <li>Provenge and DNDN have their fair share of detractors (<a href=\"https://seekingalpha.com/currents/post/1211452\" target=\"_blank\">here</a> and <a href=\"https://seekingalpha.com/currents/post/1240432\" target=\"_blank\">here</a>) but somebody seems to like today's press as the shares are trading <font color=\"green\">4%</font> higher premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302512\" data-linked=\"Dendreon to present Provenge data, shares up\" data-tweet=\"$DNDN - Dendreon to present Provenge data, shares up https://seekingalpha.com/news/1302512-dendreon-to-present-provenge-data-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/1302512-dendreon-to-present-provenge-data-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302502\" data-ts=\"1380285911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LL\" target=\"_blank\">LL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302502-lumber-liquidators-slumps-further\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lumber Liquidators slumps further</a></h4><ul> <li>Detail are still emerging on what has prompted a <a href=\"https://seekingalpha.com/currents/post/1302402\" target=\"_blank\">federal investigation</a> into Lumber Liquidators (NYSE:<a href=\"https://seekingalpha.com/symbol/LL\" title=\"Lumber Liquidators Holdings, Inc.\">LL</a>), but SA contributor Xuhua Zhou may have beaten everyone to the punch.</li> <li>Zhou <a href=\"https://seekingalpha.com/article/1513142-illegal-products-could-spell-big-trouble-at-lumber-liquidators\" target=\"_blank\">warned</a> in June that products imported by the company from China are potentially illegal and could create a headache for the company.</li> <li>That headache looks like a migraine today with the Feds at the door.</li> <li>LL <font color=\"red\">-9.5%</font> premarket</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302502\" data-linked=\"Lumber Liquidators slumps further\" data-tweet=\"$LL - Lumber Liquidators slumps further https://seekingalpha.com/news/1302502-lumber-liquidators-slumps-further?source=tweet\" data-url=\"https://seekingalpha.com/news/1302502-lumber-liquidators-slumps-further\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302492\" data-ts=\"1380285763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNX\" target=\"_blank\">CNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302492-goldman-coal-ratings-include-buy-for-consol-sell-for-arch-coal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman coal ratings include Buy for Consol, Sell for Arch Coal</a></h4><ul>     <li>Goldman Sachs picks up coverage of the coal sector (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/KOL\" title=\"VanEck Vectors Coal ETF\">KOL</a>) with a Neutral rating, as it continues to face challenges including coal plant retirements, high net debt levels and commodity prices below historical averages, but some reasons for optimism, including the bottoming of met coal prices (Briefing.com).</li>\n<li>Among individual stocks, the firm upgrades Consol Energy (NYSE:<a href=\"https://seekingalpha.com/symbol/CNX\" title=\"CNX Resources Corporation\">CNX</a>) to Buy from Neutral, lifts Alpha Natural (ANR) and Walter Energy (NYSE:<a href=\"https://seekingalpha.com/symbol/WLT\" title=\"Walter Energy, Inc.\">WLT</a>) to Neutral from Sell, downgrades Cloud Peak (NYSE:<a href=\"https://seekingalpha.com/symbol/CLD\" title=\"Cloud Peak Energy, Inc.\">CLD</a>) to Neutral from Buy, and cuts Arch Coal (NYSE:<a href=\"https://seekingalpha.com/symbol/ACI\" title=\"Albertsons Companies Inc\">ACI</a>) to Sell from Neutral.</li>     <li>In its <a href=\"http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Upgrades+CONSOL+Energy+%28CNX%29+to+Buy/8726500.html\" target=\"_blank\">upgrade</a> of CNX, Goldman cites improving cash flow from the coal segment, strong production growth from the E&amp;P segment, potential for  asset sales and restructuring, and a strong financial profile with industry-leading EBITDA  growth and solid leverage metrics; CNX <font color=\"green\">+1%</font> premarket.</li>     <li>In tagging ACI with a <a href=\"http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Assumes+Coverage+on+Arch+Coal+Inc+%28ACI%29+at+Sell%2C+Sees+33%25+Downside/8726505.html\" target=\"_blank\">Sell rating</a>, the firm cites one of the sector's highest leverage ratios, valuations near historical peak levels, a thermal outlook less  bullish than consensus, and below-average earnings growth even if met coal prices recover above forecast; ACI <font color=\"red\">-3.5%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302492\" data-linked=\"Goldman coal ratings include Buy for Consol, Sell for Arch Coal\" data-tweet=\"$CNX $KOL $CNX - Goldman coal ratings include Buy for Consol, Sell for Arch Coal https://seekingalpha.com/news/1302492-goldman-coal-ratings-include-buy-for-consol-sell-for-arch-coal?source=tweet\" data-url=\"https://seekingalpha.com/news/1302492-goldman-coal-ratings-include-buy-for-consol-sell-for-arch-coal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302472\" data-ts=\"1380285192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAA\" target=\"_blank\">UAA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302472-under-armour-higher-after-strong-numbers-from-nike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Under Armour higher after strong numbers from Nike</a></h4><ul> <li>A <a href=\"https://seekingalpha.com/currents/post/1301592\" target=\"_blank\">strong trend</a> in futures orders for Nike could bode well for Under Armour (NYSE:<a href=\"https://seekingalpha.com/symbol/UA\" title=\"Under Armour, Inc. Class C\">UA</a>).</li> <li>Though the retailer is trying to march to its own drum beat, shares of Under Armour still take a lot of cues from what's going on with global demand for products from its bigger rival.</li> <li>UA <font color=\"green\">+1.5%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302472\" data-linked=\"Under Armour higher after strong numbers from Nike\" data-tweet=\"$UAA - Under Armour higher after strong numbers from Nike https://seekingalpha.com/news/1302472-under-armour-higher-after-strong-numbers-from-nike?source=tweet\" data-url=\"https://seekingalpha.com/news/1302472-under-armour-higher-after-strong-numbers-from-nike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302432\" data-ts=\"1380284500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LL\" target=\"_blank\">LL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302432-lumber-liquidators-responds-to-federal-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lumber Liquidators responds to federal probe</a></h4><ul> <li>Lumber Liquidators (NYSE:<a href=\"https://seekingalpha.com/symbol/LL\" title=\"Lumber Liquidators Holdings, Inc.\">LL</a>) says in a statement that it's <a href=\"http://www.wavy.com/news/local/feds-execute-warrant-at-toano-business#.UkU_pFbVvoA.twitter\" target=\"_blank\">cooperating</a> with federal officials regarding their inquiry into the importation of certain products.</li> <li>LL <font color=\"red\">-6.4%</font> premarket with news of the extent of the <a href=\"https://seekingalpha.com/currents/post/1302402\" target=\"_blank\">federal investigation</a> still rather uncertain.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1302432\" data-linked=\"Lumber Liquidators responds to federal probe\" data-tweet=\"$LL - Lumber Liquidators responds to federal probe https://seekingalpha.com/news/1302432-lumber-liquidators-responds-to-federal-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/1302432-lumber-liquidators-responds-to-federal-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302412\" data-ts=\"1380284209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSL\" target=\"_blank\">TSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302412-trina-solar-yingli-green-upgraded-to-buy-at-deutsche-bank\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trina Solar, Yingli Green upgraded to Buy at Deutsche Bank</a></h4><ul>     <li>Trina Solar (NYSE:<a href=\"https://seekingalpha.com/symbol/TSL\" title=\"Trina Solar Limited\">TSL</a>) <font color=\"green\">+4.1%</font> and Yingli Green Energy (NYSE:<a href=\"https://seekingalpha.com/symbol/YGE\" title=\"Yingli Green Energy Holding Company Limited\">YGE</a>) <font color=\"green\">+3.7%</font> premarket after earnings <a href=\"http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Upgrades+Trina+Solar+%28TSL%29%2C+Yingli+Green+Energy+%28YGE%29+to+Buy+on+Accelerating+China+Demand/8726599.html\" target=\"_blank\">upgrades to Buy</a> from Hold with respective price targets of $18 and $8 at Deutsche Bank.</li>     <li>The firm cites growth rate acceleration in the Chinese solar market in H2 2013 for the upgrades, and raises 2014 EPS estimates on TSL to $1.10 and on YGE to $0.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302412\" data-linked=\"Trina Solar, Yingli Green upgraded to Buy at Deutsche Bank\" data-tweet=\"$TSL $TSL $YGE - Trina Solar, Yingli Green upgraded to Buy at Deutsche Bank https://seekingalpha.com/news/1302412-trina-solar-yingli-green-upgraded-to-buy-at-deutsche-bank?source=tweet\" data-url=\"https://seekingalpha.com/news/1302412-trina-solar-yingli-green-upgraded-to-buy-at-deutsche-bank\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302382\" data-ts=\"1380283830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302382-nektar-dives-on-phase-2-miss-naloxegol-maa-triggers-milestone-payment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar dives on Phase 2 miss, naloxegol MAA triggers milestone payment</a></h4><ul>     <li>It's a good news/ bad news type of day for Nektar Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/NKTR\" title=\"Nektar Therapeutics\">NKTR</a>), although it's safe to say investors will be taking a \"glass is half empty\" view during today's session.</li>     <li>The bad news is that the stock is down <font color=\"red\">20%</font> premarket after NKTR-181 missed its primary endpoint in a Phase 2 trial. (More on this <a href=\"https://seekingalpha.com/currents/post/1301712\" target=\"_blank\">here</a>)<br>     </li>     <li>The good news is that the EMA has <a href=\"http://www.streetinsider.com/Corporate+News/AstraZeneca+%28AZN%29+Receives+MAA+from+EMA+for+Naloxegol/8726483.html\" target=\"_blank\">accepted</a> AstraZeneca's (NYSE:<a href=\"https://seekingalpha.com/symbol/AZN\" title=\"AstraZeneca Group plc\">AZN</a>) MAA for naloxegol triggering a $25M milestone payment to NKTR. </li> </ul><div class=\"tiny-share-widget\" data-id=\"1302382\" data-linked=\"Nektar dives on Phase 2 miss, naloxegol MAA triggers milestone payment\" data-tweet=\"$NKTR $NKTR $AZN - Nektar dives on Phase 2 miss, naloxegol MAA triggers milestone payment https://seekingalpha.com/news/1302382-nektar-dives-on-phase-2-miss-naloxegol-maa-triggers-milestone-payment?source=tweet\" data-url=\"https://seekingalpha.com/news/1302382-nektar-dives-on-phase-2-miss-naloxegol-maa-triggers-milestone-payment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302312\" data-ts=\"1380282657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRYIF\" target=\"_blank\">TRYIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302312-toray-to-buy-zoltek-for-16_75-per-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toray to buy Zoltek for $16.75 per share</a></h4><ul>     <li>As tipped Thursday, Toray Industries  (<a href=\"https://seekingalpha.com/symbol/TRYIF\" title=\"Toray Industries Inc.\">OTCPK:TRYIF</a>) is <a href=\"http://www.bloomberg.com/news/2013-09-27/toray-to-buy-u-s-carbon-fiber-maker-zoltek-for-584-million.html\" target=\"_blank\">set to acquire</a> carbon fiber maker Zoltek (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ZOLT\" title=\"Zoltek Companies, Inc.\">ZOLT</a>), although the price is lower than some anticipated (the deal was <a href=\"https://seekingalpha.com/currents/post/1301362\" target=\"_blank\">originally reported</a> to be for more than $610M).</li>     <li>The purchase price is $584M, which works out to around $16.75/share in cash \u2014 that's a 9% discount to Thursday's close.</li>     <li>ZOLT <font color=\"red\">-9.8%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302312\" data-linked=\"Toray to buy Zoltek for $16.75 per share\" data-tweet=\"$TRYIF $TRYIF $ZOLT - Toray to buy Zoltek for $16.75 per share https://seekingalpha.com/news/1302312-toray-to-buy-zoltek-for-16_75-per-share?source=tweet\" data-url=\"https://seekingalpha.com/news/1302312-toray-to-buy-zoltek-for-16_75-per-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302182\" data-ts=\"1380280717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302182-details-emerge-from-j-c-penney\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Details emerge from J.C. Penney</a></h4><ul> <li>J.C Penney (NYSE:<a href=\"https://seekingalpha.com/symbol/JCP\" title=\"J.C. Penney Company Inc.\">JCP</a>) indicates up to 96.6M shares could end up getting unloaded on to the market in its common stock offering.</li> <li>The offering is priced at $9.65 per share.</li> <li>The retailer expects to end the year with $1.3B in cash.</li> <li><a href=\"http://www.sec.gov/Archives/edgar/data/1166126/000119312513380872/d604129d8k.htm\" target=\"_blank\">SEC Form 8-K</a></li> <li>JCP <font color=\"red\">-4.7%</font>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302182\" data-linked=\"Details emerge from J.C. Penney\" data-tweet=\"$JCP - Details emerge from J.C. Penney https://seekingalpha.com/news/1302182-details-emerge-from-j-c-penney?source=tweet\" data-url=\"https://seekingalpha.com/news/1302182-details-emerge-from-j-c-penney\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302132\" data-ts=\"1380279953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302132-blackberry-eps-in-line-misses-on-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry EPS in-line, misses on revenues</a></h4><ul>     <li>BlackBerry (BBRY): Q2 EPS of -$0.47 in-line.</li>\n<li>Revenue of $1.6B <font color=\"red\">misses by $0.33B</font>, but matches revised guidance. Shares  <font color=\"red\">-1.3%</font> premarket. (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1302132\" data-linked=\"BlackBerry EPS in-line, misses on revenues\" data-tweet=\"$BB - BlackBerry EPS in-line, misses on revenues https://seekingalpha.com/news/1302132-blackberry-eps-in-line-misses-on-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/1302132-blackberry-eps-in-line-misses-on-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302122\" data-ts=\"1380279601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302122-nike-rallies-following-earnings-stifel-moves-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike rallies following earnings; Stifel moves to sidelines</a></h4><ul> <li>Stifel Nicolaus downgrades Nike (NYSE:<a href=\"https://seekingalpha.com/symbol/NKE\" title=\"Nike Inc.\">NKE</a>) to a Hold rating from Buy on a valuation call.</li> <li>Previous: <a href=\"https://seekingalpha.com/currents/post/1301522\" target=\"_blank\">earnings</a>, <a href=\"https://seekingalpha.com/currents/post/1301592\" target=\"_blank\">wrapup</a>\n</li>\n<li>NKE <font color=\"green\">+5.5%</font> premarket to $74.20, marking new all-time highs.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1302122\" data-linked=\"Nike rallies following earnings; Stifel moves to sidelines\" data-tweet=\"$NKE - Nike rallies following earnings; Stifel moves to sidelines https://seekingalpha.com/news/1302122-nike-rallies-following-earnings-stifel-moves-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/1302122-nike-rallies-following-earnings-stifel-moves-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302102\" data-ts=\"1380279024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302102-j-c-penney-slumps-in-early-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney slumps in early trading</a></h4><ul> <li>The <a href=\"http://www.streetinsider.com/Corporate+News/Expected+Range+on+JCPenney+%28JCP%29+Offering+about+%249.35+-+%249.75Share/8726492.html\" target=\"_blank\">expected price range</a> of J.C. Penney's (NYSE:<a href=\"https://seekingalpha.com/symbol/JCP\" title=\"J.C. Penney Company Inc.\">JCP</a>) 84M common stock offering is $9.35-$9.75, according to the scuttlebutt on Wall Street.</li> <li>JCP <font color=\"red\">-9.2%</font> to $9.46 premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1302102\" data-linked=\"J.C. Penney slumps in early trading\" data-tweet=\"$JCP - J.C. Penney slumps in early trading https://seekingalpha.com/news/1302102-j-c-penney-slumps-in-early-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/1302102-j-c-penney-slumps-in-early-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302062\" data-ts=\"1380272616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302062-boe-chief-carney-rules-out-more-qe-for-now\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BOE chief Carney rules out more QE for now</a></h4><ul>     <li>Bank of England Governor Mark Carney doesn't believe the BOE needs to restart its bond-buying program, due to the improvement in the U.K. economy.</li>     <li>\"Given the recovery has strengthened and broadened, <a href=\"http://www.yorkshirepost.co.uk/business/business-news/yorkshire-can-reap-benefits-from-turnaround-says-mark-carney-1-6089216\" target=\"_blank\">I don't see a case</a> for quantitative easing and I have not supported it,\" Carney told the <i>Yorkshire Post</i> regional newspaper. However, the BOE would consider more QE should the economy falter.</li>\n<li>The pound is <font color=\"green\">+0.1%</font> at $1.6063, although that's down from earlier highs. The FTSE is <font color=\"red\">-0.3%</font>.</li>     <li>ETFs - Stocks: <a href=\"https://seekingalpha.com/symbol/fku\" title=\"First Trust United Kingdom AlphaDex ETF\">FKU</a>, <a href=\"https://seekingalpha.com/symbol/ewu\" title=\"iShares MSCI United Kingdom ETF\">EWU</a>, <a href=\"https://seekingalpha.com/symbol/ewus\" title=\"iShares MSCI United Kingdom Small Cap Index ETF\">EWUS</a>, <a href=\"https://seekingalpha.com/symbol/dxps\" title=\"WisdomTree United Kingdom Hedged Equity ETF\">DXPS</a>. Currency: <a href=\"https://seekingalpha.com/symbol/gbb\" title=\"iPath GBP/USD Exchange Rate ETN\">GBB</a>, <a href=\"https://seekingalpha.com/symbol/fxb\" title=\"CurrencyShares British Pound Sterling Trust ETF\">FXB</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302062\" data-linked=\"BOE chief Carney rules out more QE for now\" data-tweet=\"$FKU $EWU $EWUS - BOE chief Carney rules out more QE for now https://seekingalpha.com/news/1302062-boe-chief-carney-rules-out-more-qe-for-now?source=tweet\" data-url=\"https://seekingalpha.com/news/1302062-boe-chief-carney-rules-out-more-qe-for-now\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302032\" data-ts=\"1380270932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302032-asian-shares-mixed-eu-stocks-u-s-futures-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asian shares mixed; EU stocks, U.S. futures lower</a></h4><ul>     <li>Asian stocks are mixed as Japanese shares fall following data showing that \"core-core CPI\" <a href=\"https://seekingalpha.com/currents/post/1301962\" target=\"_blank\">remains negative</a>.</li>     <li>Chinese equities rise after <a href=\"https://seekingalpha.com/currents/post/1302012\" target=\"_blank\">growth in industrial profits</a> provide further evidence that the economy is improving. Australian stocks hit another five year high.</li>     <li>European shares are lower ahead of consumer confidence data.</li>     <li>U.S. stock futures fall as the impasse in Washington over the budget and the debt ceiling shows <a href=\"https://seekingalpha.com/currents/post/1301982\" target=\"_blank\">no signs of abating</a>.</li>     <li>Japan <font color=\"red\">-0.3%</font>, Hong Kong <font color=\"green\">+0.3%</font>, China <font color=\"green\">+0.2%</font>, India <font color=\"red\">-0.2%</font>, Australia <font color=\"green\">+0.3%.</font>\n</li>    <li>EU Stoxx 50 flat, London <font color=\"red\">-0.3%</font>, Paris <font color=\"red\">-0.1%</font>, Frankfurt <font color=\"red\">-0.1%</font>, Milan <font color=\"red\">-0.1%</font>, Madrid <font color=\"red\">-0.2%</font>.</li>      <li>Dow <font color=\"red\">-0.1%</font>, S&amp;P <font color=\"red\">-0.2%</font>, Nasdaq <font color=\"red\">-0.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302032\" data-linked=\"Asian shares mixed; EU stocks, U.S. futures lower\" data-tweet=\"Asian shares mixed; EU stocks, U.S. futures lower https://seekingalpha.com/news/1302032-asian-shares-mixed-eu-stocks-u-s-futures-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/1302032-asian-shares-mixed-eu-stocks-u-s-futures-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1302002\" data-ts=\"1380268381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1302002-kerry-holds-one-on-one-talks-with-iranian-foreign-minister\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kerry holds one-on-one talks with Iranian foreign minister</a></h4><ul>     <li>U.S. Secretary of State John Kerry and Iranian Foreign Minister Mohammad Javad Zarif had a private discussion over Iran's nuclear program yesterday at the U.N. in New York in what was the <a href=\"http://www.reuters.com/article/2013/09/27/us-un-assembly-iran-idUSBRE98P0XE20130927\" target=\"_blank\">highest-level official meeting</a> between the countries since before the Islamic Revolution in 1979.</li>     <li>Kerry said the talks, which came after wider negotiations between Iran and major international powers, were \"constructive.\" However, he warned that much work was needed to be done, with the U.S. wanting clear proof that Iran was not developing nuclear weapons before sanctions would be eased.</li>     <li>Despite the caution, the improved relations <a href=\"http://www.marketwatch.com/story/oil-futures-get-back-to-their-losing-ways-2013-09-27\" target=\"_blank\">helped send</a> oil <font color=\"red\">0.5% lower</font> to $102.49.</li>     <li>ETFs: <a href=\"https://seekingalpha.com/symbol/jje\" title=\"iPath DJ-UBS Energy Total Return Sub-Index ETN\">JJE</a>, <a href=\"https://seekingalpha.com/symbol/rjn\" title=\"ELEMENTS Rogers International Commodity Energy ETN\">RJN</a>, <a href=\"https://seekingalpha.com/symbol/dbe\" title=\"PowerShares DB Energy ETF\">DBE</a>, <a href=\"https://seekingalpha.com/symbol/ubn\" title=\"UBS E-TRACS CMCI Energy Total Return ETN\">UBN</a>, <a href=\"https://seekingalpha.com/symbol/rgre\" title=\"RBS Rogers Enhanced Energy ETN\">RGRE</a>, <a href=\"https://seekingalpha.com/symbol/oil\" title=\"iPath S&amp;P Crude Oil Total Return Index ETN\">OIL</a>, <a href=\"https://seekingalpha.com/symbol/uso\" title=\"The United States Oil ETF, LP\">USO</a>, <a href=\"https://seekingalpha.com/symbol/dbo\" title=\"PowerShares DB Oil ETF\">DBO</a>, <a href=\"https://seekingalpha.com/symbol/olo\" title=\"PowerShares DB Crude Oil Long ETN\">OLO</a>, <a href=\"https://seekingalpha.com/symbol/usl\" title=\"The United States 12 Month Oil ETF, LP\">USL</a>, <a href=\"https://seekingalpha.com/symbol/crud\" title=\"Teucrium WTI Crude Oil ETF\">CRUD</a>, <a href=\"https://seekingalpha.com/symbol/uco\" title=\"ProShares Ultra DJ-UBS Crude Oil ETF\">UCO</a>, <a href=\"https://seekingalpha.com/symbol/dto\" title=\"PowerShares DB Crude Oil Double Short ETN\">DTO</a>, <a href=\"https://seekingalpha.com/symbol/sco\" title=\"ProShares UltraShort DJ-UBS Crude Oil ETF\">SCO</a>, <a href=\"https://seekingalpha.com/symbol/szo\" title=\"PowerShares DB Crude Oil Short ETN\">SZO</a>, <a href=\"https://seekingalpha.com/symbol/dno\" title=\"The United States Short Oil ETF, LP\">DNO</a>, <a href=\"https://seekingalpha.com/symbol/uwti\" title=\"VelocityShares 3x Long Crude Oil ETN\">UWTI</a>, <a href=\"https://seekingalpha.com/symbol/dwti\" title=\"VelocityShares 3x Inverse Crude Oil ETN\">DWTI</a>, <a href=\"https://seekingalpha.com/symbol/bno\" title=\"The United States Brent Oil ETF, LP\">BNO</a>, <a href=\"https://seekingalpha.com/symbol/uoil\" title=\"VelocityShares 3x Long Brent Crude ETN\">UOIL</a>, <a href=\"https://seekingalpha.com/symbol/doil\" title=\"VelocityShares 3x Inverse Brent Crude ETN\">DOIL</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1302002\" data-linked=\"Kerry holds one-on-one talks with Iranian foreign minister\" data-tweet=\"$JJE $RJN $DBE - Kerry holds one-on-one talks with Iranian foreign minister https://seekingalpha.com/news/1302002-kerry-holds-one-on-one-talks-with-iranian-foreign-minister?source=tweet\" data-url=\"https://seekingalpha.com/news/1302002-kerry-holds-one-on-one-talks-with-iranian-foreign-minister\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1301962\" data-ts=\"1380263374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1301962-japanese-core-inflation-rises-to-highest-level-in-five-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Japanese core inflation rises to highest level in five years</a></h4><ul>   <li>\n<a href=\"http://www.bloomberg.com/news/2013-09-26/japan-inflation-accelerates-to-fastest-pace-since-2008-on-energy.html\" target=\"_blank\">Japanese CPI</a> +0.9% on year in August vs +0.7% in July and consensus of +0.8%.</li>    <li>Core CPI, excluding fresh food, rose to its highest level since November 2008, increasing to +0.8% vs +0.7 and +0.7%. The gain also represented third straight month of growth.</li>    <li>However, most of the increase was due to rising gasoline prices and the weaker yen.</li>    <li>Core-core CPI, which excludes energy as well, -0.1% vs -0.1% and -0.1%.</li>    <li>The prices of consumer-electronic equipment and other durable leisure goods rose 0.1%, the first increase since 1992.</li>    <li>For inflation to take hold, wages need to start rising, economists say. PM Shinzo Abe \"will have to keep up his campaign on companies for wage growth,\" says Taro Saito.</li>    <li>Japan 225 <font color=\"red\">-0.4%</font>; USD-JPY <font color=\"red\">-0.4%</font> to ¥98.65. (PR)</li>    <li>ETFs - Stocks: <a href=\"https://seekingalpha.com/symbol/ewj\" title=\"iShares MSCI Japan ETF\">EWJ</a>, <a href=\"https://seekingalpha.com/symbol/nky\" title=\"Precidian MAXIS Nikkei 225 Index ETF\">NKY</a>, <a href=\"https://seekingalpha.com/symbol/ewv\" title=\"ProShares UltraShort MSCI Japan ETF\">EWV</a>, <a href=\"https://seekingalpha.com/symbol/ezj\" title=\"ProShares Ultra MSCI Japan ETF\">EZJ</a>, <a href=\"https://seekingalpha.com/symbol/itf\" title=\"iShares Japan Large-Cap ETF\">ITF</a>, <a href=\"https://seekingalpha.com/symbol/jsc\" title=\"SPDR Russell/Nomura Small Cap Japan ETF\">JSC</a>, <a href=\"https://seekingalpha.com/symbol/jpp\" title=\"SPDR Russell/Nomura PRIME Japan ETF\">JPP</a>, <a href=\"https://seekingalpha.com/symbol/dxj\" title=\"WisdomTree Japan Hedged Equity ETF\">DXJ</a>, <a href=\"https://seekingalpha.com/symbol/scj\" title=\"iShares MSCI Japan Small-Cap ETF\">SCJ</a>, <a href=\"https://seekingalpha.com/symbol/dfj\" title=\"WisdomTree Japan SmallCap Dividend ETF\">DFJ</a>, <a href=\"https://seekingalpha.com/symbol/fjp\" title=\"First Trust Japan AlphaDEX ETF\">FJP</a>, <a href=\"https://seekingalpha.com/symbol/jpnl\" title=\"Direxion Daily Japan Bull 3x Shares ETF\">JPNL</a>, <a href=\"https://seekingalpha.com/symbol/jpns\" title=\"Direxion Daily Japan Bear 3x Shares ETF\">JPNS</a>, <a href=\"https://seekingalpha.com/symbol/dxjs\" title=\"WisdomTree Japan Hedged SmallCap Equity ETF\">DXJS</a>. Bonds: <a href=\"https://seekingalpha.com/symbol/jgbt\" title=\"PowerShares DB 3x Japanese Government Bond Futures ETN\">JGBT</a>, <a href=\"https://seekingalpha.com/symbol/jgbl\" title=\"PowerShares DB Japanese Government Bond Futures ETN\">JGBL</a>, <a href=\"https://seekingalpha.com/symbol/jgbs\" title=\"PowerShares DB Inverse Japanese Govt. Bond Futures ETN\">JGBS</a>, <a href=\"https://seekingalpha.com/symbol/jgbd\" title=\"PowerShares DB 3x Inverse Japanese Govt. Bond Futures ETN\">JGBD</a>. Currency: <a href=\"https://seekingalpha.com/symbol/fxy\" title=\"CurrencyShares Japanese Yen Trust ETF\">FXY</a>, <a href=\"https://seekingalpha.com/symbol/jyn\" title=\"iPath JPY/USD Exchange Rate ETN\">JYN</a>, <a href=\"https://seekingalpha.com/symbol/ycl\" title=\"ProShares Ultra Yen ETF\">YCL</a>, <a href=\"https://seekingalpha.com/symbol/ycs\" title=\"ProShares UltraShort Yen ETF\">YCS</a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"1301962\" data-linked=\"Japanese core inflation rises to highest level in five years\" data-tweet=\"$EWJ $NKY $EWV - Japanese core inflation rises to highest level in five years https://seekingalpha.com/news/1301962-japanese-core-inflation-rises-to-highest-level-in-five-years?source=tweet\" data-url=\"https://seekingalpha.com/news/1301962-japanese-core-inflation-rises-to-highest-level-in-five-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 AM </div></div></li>","count":51,"message":null,"success":true,"today":{"start":1576818000,"end":1576904399,"str":"Friday, December 20, 2019"},"yesterday":{"start":1576731600,"end":1576817999}}